Eikon Therapeutics Inc., a late-stage clinical biopharmaceutical company, is expected to begin trading on the Nasdaq Global Select Market on February 5, 2026, under the ticker symbol "EIKN".
The company will offer 21.18 million shares of its common stock at an initial public offering price of $18.00 per share. The offering is expected to close on or about February 6, 2026, and rake in gross proceeds of roughly $381 million.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.